COVID-19 Related Coagulopathy : What is Known Up to Now
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has been a global challenge. The complicated forms of the Coronavirus Disease 2019 (COVID- 19) can evolve to multiple-organ failure, including several coagulopathies related to a sudden worsening of respiratory status. This article aimed to review studies about hematological and hemostatic laboratory disorders directly related to COVID-19 and to discuss how SARS-CoV- 2 causes these abnormalities. The coagulation cascade model is associated with both COVID- 19 and pulmonary involvement. Laboratory changes are relevant to evaluate the coagulation state - D-dimer, prothrombin time (PT), Activated Partial Thromboplastin Time (APTT), platelet count and fibrinogen. Pregnant women and patients in Extracorporeal Membrane Oxygenation (ECMO) need special attention. Prophylactic interventions for COVID-19 coagulopathy should consider patients at risk for thrombotic events and potential contraindications. The mechanisms exerted by SARS-CoV-2 that impairs hemostatic balance include endothelial injury, inflammation, and activation of the immune and complement systems. For diagnosis of coagulopathy, mainly D-dimer, but also PT, APTT and FDP, should be evaluated in COVID-19 patients. Intervention possibilities vary between low-molecular-weight heparin (LMWH) and Unfractionated Heparin (UFH). Until now, there is sufficient evidence that acutely-ill patients with risk factors for coagulopathies will benefit from thrombophylaxis during hospitalization and post-discharge, but not all patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Current medicinal chemistry - 28(2021), 21 vom: 31., Seite 4207-4225 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pena, Ana Luísa Batista [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9005-49-6 |
|---|
| Anmerkungen: |
Date Completed 19.07.2021 Date Revised 31.05.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/0929867327666201005112231 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315901616 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315901616 | ||
| 003 | DE-627 | ||
| 005 | 20231225155918.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0929867327666201005112231 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1052.xml |
| 035 | |a (DE-627)NLM315901616 | ||
| 035 | |a (NLM)33019920 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pena, Ana Luísa Batista |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Related Coagulopathy |b What is Known Up to Now |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.07.2021 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has been a global challenge. The complicated forms of the Coronavirus Disease 2019 (COVID- 19) can evolve to multiple-organ failure, including several coagulopathies related to a sudden worsening of respiratory status. This article aimed to review studies about hematological and hemostatic laboratory disorders directly related to COVID-19 and to discuss how SARS-CoV- 2 causes these abnormalities. The coagulation cascade model is associated with both COVID- 19 and pulmonary involvement. Laboratory changes are relevant to evaluate the coagulation state - D-dimer, prothrombin time (PT), Activated Partial Thromboplastin Time (APTT), platelet count and fibrinogen. Pregnant women and patients in Extracorporeal Membrane Oxygenation (ECMO) need special attention. Prophylactic interventions for COVID-19 coagulopathy should consider patients at risk for thrombotic events and potential contraindications. The mechanisms exerted by SARS-CoV-2 that impairs hemostatic balance include endothelial injury, inflammation, and activation of the immune and complement systems. For diagnosis of coagulopathy, mainly D-dimer, but also PT, APTT and FDP, should be evaluated in COVID-19 patients. Intervention possibilities vary between low-molecular-weight heparin (LMWH) and Unfractionated Heparin (UFH). Until now, there is sufficient evidence that acutely-ill patients with risk factors for coagulopathies will benefit from thrombophylaxis during hospitalization and post-discharge, but not all patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Acute respiratory distress syndrome | |
| 650 | 4 | |a Angiotensin-convertingenzyme 2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Coagulation | |
| 650 | 4 | |a Coagulopathy | |
| 650 | 4 | |a SARS-CoV-2. | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 650 | 7 | |a Heparin |2 NLM | |
| 650 | 7 | |a 9005-49-6 |2 NLM | |
| 700 | 1 | |a Oliveira, Rafael Arantes |e verfasserin |4 aut | |
| 700 | 1 | |a Severo, Renata Gomes |e verfasserin |4 aut | |
| 700 | 1 | |a Simões E Silva, Ana Cristina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current medicinal chemistry |d 1997 |g 28(2021), 21 vom: 31., Seite 4207-4225 |w (DE-627)NLM093833857 |x 1875-533X |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2021 |g number:21 |g day:31 |g pages:4207-4225 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0929867327666201005112231 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2021 |e 21 |b 31 |h 4207-4225 | ||